Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial
Journal of Atherosclerosis and Thrombosis · 2025
DOI: 10.5551/jat.64112 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Atherosclerosis and Thrombosis, 2025. Verfasst von Wenli Dai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Anzhen Hospital, Capital Medical University. Hauptthemen laut MEDLINE: Benzoxazoles, PPAR alpha, Butyrates, Dyslipidemias. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Anzhen Hospital, Capital Medical University.
- Chengdu Xinhua Hospital.
- The First Affiliated Hospital of Harbin Medical University.
- Pingxiang People's Hospital.
- The Third Hospital of Changsha.
- The First Hospital of Anhui University of Science and Technology.
Zitieren
APA
Dai, W., Lv, Q., Li, Q., Fu, L., Zhang, Y., Zhang, Y., Liu, L., Tanigawa, R., Kunitomi, K., Kamei, R., Suganami, H., & Ma, C. (2025). Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.64112
Vancouver
Dai W, Lv Q, Li Q, Fu L, Zhang Y, Zhang Y, et al. Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial. Journal of Atherosclerosis and Thrombosis. 2025. doi:10.5551/jat.64112
BibTeX
@article{Dai2025,
author = {Dai, Wenli and Lv, Qiang and Li, Qingling and Fu, Lu and Zhang, Yawei and Zhang, Yumin and Liu, Lijun and Tanigawa, Ryohei and Kunitomi, Keisuke and Kamei, Ryo and Suganami, Hideki and Ma, Changsheng},
title = {Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial},
journal = {Journal of Atherosclerosis and Thrombosis},
year = {2025},
doi = {10.5551/jat.64112}
}
EUVIMED